Skip to Main Content

This story is part of STAT’s quarterly series Something Ventured, which looks at early-stage startups. You can read the earlier stories in the series here

Private biotech companies tend to be, well, private. That might explain why so many barely make a public peep after raising millions of dollars from venture capital firms. Few early-stage biotech companies in the Boston area issue more than a handful of press releases every year.


But that doesn’t mean the companies and their executives aren’t keeping busy. This time last year, resTORbio (TORC) and Neon Therapeutics (NTGN) were still private companies. KSQ Therapeutics had just raised a $76 million round in October 2017 — that company just raised another $80 million this September.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.